Company intelligence / Profile preview

Dr. Max Pharma

Prague, Praha, Czech Republicdrmax.eu ↗

Ownership: Private
Development stage: Commercial

Overview

Dr. Max Pharma is the largest pharmaceutical producer in the Czech Republic as of 2023 and a leading private label manufacturer for the extensive Dr. Max pharmacy chain across Central and Eastern Europe. The company reported a 34% revenue growth in 2023 with over 84 million products sold that year across six markets[5]. Its portfolio includes nearly 300 drug registrations and around 1,300 SKUs spanning medicines and non-medicines.

Therapeutic areas: Other
Modalities: Over-the-counter medicines (OTC)Unbranded generics (Gx, small molecules)Food supplements (vitamins, minerals, probiotics)Medical devices
Industry: Non-Academic Healthcare

Partnerships

Collaborates with global suppliers for product development/manufacturing; no major pharma/biotech partnerships disclosed by name[1][4].

Beyond the preview

Go deeper on Dr. Max Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dr. Max Pharma.

Explore the full profile